02/15/2026
STAY INFORMED.
From the FDA DESK: On February 10, 2026, the U.S. Food and Drug Administration approved pembrolizumab as well as pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for adult patients with PLATINUM RESISTANT epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.
This win comes out of the multi-center and multi-national KEYNOTE-B96 trial! Ask your questions directly to the Expert Dr. Matulonis on our upcoming OC 360 LIVE on March 4! RSVPs opening soon!
Let's keep hoping, let's keep Ovarcoming 🩵
READ:
https://www.fiercepharma.com/pharma/merck-pushes-keytruda-across-fda-finish-line-its-first-ovarian-cancer-nod
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-paclitaxel-platinum-resistant-epithelial-ovarian-fallopian-tube-or